Clinical development of therapeutic approaches aiming to increase dystrophin levels requires sensitive and reproducible measurement of differences in dystrophin expression in muscle biopsies of treated patients with DMD. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.